New York | US regulators have fully approved the first Alzheimer’s drug to slow progression of the disease, a move that will pave the way for millions of American patients to access treatment.
The broader clearance from the Food and Drug Administration marks a milestone for treatment of the dementia that afflicts 6 million Americans.
